MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies, Inc. announced today the results of several preclinical studies of GX15-070, a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis. The data indicated that GX15-070 induced apoptosis in several types of hematological cancer cell lines, both as a single agent and in combination with other cancer drugs such as rituximab, proteasome inhibitors, other Bcl-2 inhibitors, and chemotherapy agents such as CDDP and doxorubicin. The data were presented as five separate posters at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition, December 9-12, 2006 in Orlando, FL.
